Cabozantinib (Cometriq)
Jump to navigation
Jump to search
FDA approved 11/29/2012. Also known as XL184 or XL-184.
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Clinical trials
- Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
- Safety Study of XL184 (Cabozantinib) in Combination With Temozolomide and Radiation Therapy in the Initial Treatment of Adults With Glioblastoma
- A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer
- Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM)
- A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors
- Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme
- Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
- XL-184+Abiraterone in Post-Chemo CRPC
- Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone
- Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2)
Patient drug information
- Cabozantinib (Cometriq) package insert pages 20-24[1] (the numbering for the PDF is off, so in some PDF viewers, the patient information is on pages 27-31)
- Cabozantinib (Cometriq) patient drug information (Chemocare)[4]
- Cabozantinib (Cometriq) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 11/29/2012: FDA approved for treatment of "progressive metastatic medullary thyroid cancer (MTC)"